RxDoctor Payments Data

Megha Mendiratta, MD

Family Medicine · Washington, DCNPI 1184985418

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,795 of the $6,015 with a category attached, or 79.7%. 32 manufacturers reported payments, led by AbbVie at 24.4% of the total. Reporting peaked in 2021 at $1,809 and has fallen 78.6% since, to $387 in 2025. Among family medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,015in general payments, 2019–2025

Across 239 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Gilead$498
  • Pfizer$332
  • Takeda Pharmaceuticals U.S.A., Inc.$309
  • Biohaven Pharmaceutical Holding Company Ltd.$289
  • plus $2K from 26 others

What the payments were for

  • Consulting fees$1,20020%
  • Travel & lodging$200%
  • Food & beverage$4,79580%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,015 in reported general payments places this provider in the 95th percentile of 166 family medicine providers in District of Columbia.

See all family medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$12,433
Medicare patients
42
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$1,242
Rosuvastatin Calcium35$1,233
Venlafaxine Hcl ErVenlafaxine Hcl12$277
Omeprazole13$171
Levothyroxine Sodium19$165
Metoprolol Succinate14$145
Ezetimibe14$143
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide11$86
Amlodipine Besylate34$78
Atorvastatin Calcium19$52
Losartan Potassium11$44
Clonazepam14$43

Paid to pharmacies, not to this prescriber.

Other family medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →